Literature DB >> 16439039

Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants.

María Jesús Grilló1, Lorea Manterola, María Jesús de Miguel, Pilar María Muñoz, José María Blasco, Ignacio Moriyón, Ignacio López-Goñi.   

Abstract

The Brucella abortus S19 and RB51 strains are the most widely used live vaccines against bovine brucellosis. However, both can induce abortion and milk excretion, S19 vaccination interferes in serological tests, and RB51 is less effective. We have shown previously that a rough wbkAB. abortus mutant is attenuated and a better vaccine than RB51 in BALB/c mice, and that mutants in the two-component regulatory system bvrS/bvrR are markedly attenuated while keeping a smooth lipopolysaccharide (S-LPS). In this work, we tested whether simultaneous inoculation with live bvrS increases wbkA vaccine efficacy in mice. Even at high doses, the bvrS mutant was cleared much faster from spleens than the wbkA mutant. The splenic persistence of the wbkA mutant increased when inoculated along with the bvrS mutant, but also with inactivated bvrS cells or with purified B. abortus S-LPS, strongly suggesting that S-LPS in the bvrS mutant played a determinant role in the wbkA persistence. When inoculated alone, both mutants protected against virulent B. abortus but less than when inoculated simultaneously, and the protection afforded by the combination was better than that obtained with B. abortus S19. Increased protection was also obtained after simultaneous inoculation of the wbkA mutant and inactivated bvrS cells or purified S-LPS, showing again the role played by the S-LPS in the bvrS cells. In mice, the bvrS-wbkA combination induced an antibody response reduced with respect to B. abortus S19 vaccination. Thus, the simultaneous use of live bvrS and wbkA B. abortus mutants seems a promising approach to overcome the problems of the S19 andRB51 vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439039     DOI: 10.1016/j.vaccine.2005.12.038

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; Y Fan; M M Kahl-McDonagh; T A Ficht
Journal:  Clin Vaccine Immunol       Date:  2011-12-14

2.  Development of a selective culture medium for primary isolation of the main Brucella species.

Authors:  M J De Miguel; C M Marín; P M Muñoz; L Dieste; M J Grilló; J M Blasco
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

3.  Altered Transcriptome of the B. melitensis Vaccine Candidate 16MΔvjbR, Implications for Development of Genetically Marked Live Vaccine.

Authors:  Yuehua Ke; Yufei Wang; Xitong Yuan; Zhijun Zhong; Qing Qu; Dongsheng Zhou; Xiaotao Zeng; Jie Xu; Zhoujia Wang; Xinying Du; Tongkun Wang; Ruifu Yang; Qing Zhen; Yaqin Yu; Liuyu Huang; Zeliang Chen
Journal:  Indian J Microbiol       Date:  2012-08-02       Impact factor: 2.461

4.  Brucella canis is an intracellular pathogen that induces a lower proinflammatory response than smooth zoonotic counterparts.

Authors:  Carlos Chacón-Díaz; Pamela Altamirano-Silva; Gabriela González-Espinoza; María-Concepción Medina; Alejandro Alfaro-Alarcón; Laura Bouza-Mora; César Jiménez-Rojas; Melissa Wong; Elías Barquero-Calvo; Norman Rojas; Caterina Guzmán-Verri; Edgardo Moreno; Esteban Chaves-Olarte
Journal:  Infect Immun       Date:  2015-10-05       Impact factor: 3.441

5.  Immunization with Brucella VirB proteins reduces organ colonization in mice through a Th1-type immune response and elicits a similar immune response in dogs.

Authors:  Cora N Pollak; María Magdalena Wanke; Silvia M Estein; M Victoria Delpino; Norma E Monachesi; Elida A Comercio; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

6.  Brucella abortus depends on pyruvate phosphate dikinase and malic enzyme but not on Fbp and GlpX fructose-1,6-bisphosphatases for full virulence in laboratory models.

Authors:  Amaia Zúñiga-Ripa; Thibault Barbier; Raquel Conde-Álvarez; Estrella Martínez-Gómez; Leyre Palacios-Chaves; Yolanda Gil-Ramírez; María Jesús Grilló; Jean-Jacques Letesson; Maite Iriarte; Ignacio Moriyón
Journal:  J Bacteriol       Date:  2014-06-16       Impact factor: 3.490

7.  Genome sequences of three live attenuated vaccine strains of Brucella species and implications for pathogenesis and differential diagnosis.

Authors:  Yufei Wang; Yuehua Ke; Zhoujia Wang; Xitong Yuan; Yefeng Qiu; Qing Zhen; Jie Xu; Tiefeng Li; Dali Wang; Liuyu Huang; Zeliang Chen
Journal:  J Bacteriol       Date:  2012-11       Impact factor: 3.490

Review 8.  What have we learned from brucellosis in the mouse model?

Authors:  María-Jesús Grilló; José María Blasco; Jean Pierre Gorvel; Ignacio Moriyón; Edgardo Moreno
Journal:  Vet Res       Date:  2012-04-13       Impact factor: 3.683

9.  The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice.

Authors:  Beatriz San Román; Victoria Garrido; Pilar-María Muñoz; Laura Arribillaga; Begoña García; Ximena De Andrés; Virginia Zabaleta; Cristina Mansilla; Inmaculada Farrán; Iñigo Lasa; Damián De Andrés; Beatriz Amorena; Juan-José Lasarte; María-Jesús Grilló
Journal:  Vet Res       Date:  2012-04-19       Impact factor: 3.683

10.  Brucella abortus ornithine lipids are dispensable outer membrane components devoid of a marked pathogen-associated molecular pattern.

Authors:  Leyre Palacios-Chaves; Raquel Conde-Álvarez; Yolanda Gil-Ramírez; Amaia Zúñiga-Ripa; Elías Barquero-Calvo; Carlos Chacón-Díaz; Esteban Chaves-Olarte; Vilma Arce-Gorvel; Jean-Pierre Gorvel; Edgardo Moreno; María-Jesús de Miguel; María-Jesús Grilló; Ignacio Moriyón; Maite Iriarte
Journal:  PLoS One       Date:  2011-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.